sever
acut
respiratori
syndrom
sar
emerg
epidem
asia
winter
quickli
spread
throughout
world
etiolog
agent
soon
identifi
new
coronaviru
sarscov
plagu
end
juli
death
toll
patient
probabl
diagnos
http
diseas
signific
impact
intern
social
econom
activ
addit
like
reemerg
sar
seriou
concern
potenti
misus
biolog
weapon
four
year
identif
howev
mani
patholog
aspect
viru
yet
character
entri
envelop
virus
cell
known
occur
via
two
primari
pathway
virus
deliv
genom
cytosol
envelop
fuse
plasma
membran
cell
surfac
wherea
other
take
advantag
cell
endocyt
machineri
latter
mechan
endocytos
virion
subject
activ
step
endosom
typic
mediat
acid
endosom
ph
result
fusion
viral
endosom
membran
releas
viral
genom
cytosol
therefor
endocyt
mechan
thought
phsensit
process
direct
membran
fusion
phindepend
endocyt
pathway
exploit
anim
virus
gain
entri
host
cell
includ
macropinocytosi
clathrindepend
endocytosi
caveolaedepend
endocytosi
well
poorli
character
rout
clathrin
caveolaeindepend
endocytosi
although
virus
use
one
pathway
enter
cell
recent
studi
shown
virus
use
multipl
mechan
gain
entri
host
cell
entri
sarscov
cell
first
identifi
occur
direct
fusion
plasma
membran
later
studi
shown
entri
sarscov
may
phdepend
endosom
proteas
cathepsin
l
might
involv
suggest
viru
may
employ
endocytosi
conflict
result
obtain
variou
research
group
use
similar
experiment
method
fluorospectrometr
monitor
gfplabel
pseudoviru
entri
host
cell
decid
use
differ
approach
label
sarscov
function
receptor
angiotensin
convert
enzym
gfp
stabl
transfect
human
embryon
kidney
cell
receptor
recycl
track
cell
treat
pseudovirus
spike
protein
membran
compon
sarscov
mediat
membran
fusion
requir
viral
entri
new
approach
greatli
improv
experiment
stabil
reliabl
result
show
sarscov
enter
cell
via
receptordepend
phsensit
endocytosi
also
show
specif
endocyt
pathway
use
sarscov
enter
cell
clathrin
caveolaeindepend
moreov
lipid
raft
found
play
import
role
process
result
provid
insight
patholog
characterist
newli
emerg
viru
order
examin
entri
sarscov
cell
cell
line
first
gener
stabli
express
fuse
either
myc
tag
gfp
express
cell
line
confirm
western
blot
supplementari
inform
figur
receptor
express
cell
line
directli
visual
fluoresc
figur
show
local
primarili
cell
surfac
suggest
express
local
cell
line
similar
vero
cell
cell
line
allow
direct
track
movement
receptor
fluoresc
microscop
agreement
previou
report
show
express
nonpermiss
cell
render
permiss
infect
stabl
cell
line
infect
spikebear
pseudovirus
supplementari
inform
figur
first
test
whether
spike
protein
alon
could
enter
cell
use
cell
line
sinc
spike
protein
believ
mediat
viru
entri
purifi
recombin
spike
protein
fuse
human
igg
fc
fragment
ad
cell
incub
h
number
gfpcontain
vesicl
observ
perinuclear
area
figur
wherea
vesicl
observ
control
cell
treat
fc
protein
alon
figur
suggest
spike
protein
specif
induc
transloc
cell
surfac
interior
cell
statist
analysi
percentag
cell
vesicl
accumul
show
signific
differ
effect
treatment
viru
entri
supplementari
inform
figur
dual
stain
assay
spike
protein
show
coloc
two
protein
figur
suggest
spike
protein
bound
vesicl
spike
protein
taken
cell
like
endocytosi
fact
spike
protein
induc
transloc
cell
surfac
intracellular
compart
agreement
previou
find
surfac
express
vero
cell
decreas
incub
spike
protein
h
addit
incub
receptorcontain
vesicl
longer
visibl
within
cell
green
signal
instead
seen
cluster
near
cell
surfac
suggest
receptor
recycl
figur
process
block
lysosomotrop
agent
report
function
elev
ph
acid
compart
therebi
inhibit
dissoci
ligand
receptor
trap
receptor
endosom
found
treatment
ammonium
chlorid
bafilomycin
chloroquin
viral
receptor
trap
within
perinuclear
vacuol
even
incub
period
would
allow
receptor
recycl
cell
surfac
normal
condit
figur
unpublish
data
result
reflect
normal
traffic
membran
flow
cargo
first
intern
besieg
membran
fuse
earli
endosom
late
endosom
cargo
dissoci
receptor
receptor
usual
recycl
back
cell
membran
cargo
target
lysosom
due
highli
contagi
natur
sarscov
use
spike
proteinbear
pseudovirus
studi
viru
entri
rout
pseudovirus
often
use
mimic
entri
real
virus
hepat
c
viru
ebola
viru
marburg
viru
host
cell
strategi
power
tool
studi
earli
event
life
cycl
viru
therefor
use
retrovir
pseudovirus
bear
sarscov
spike
protein
infect
cell
incub
gfpcontain
vesicl
detect
within
cell
figur
intracellular
vesicl
cell
line
treat
control
pseudoviru
bear
vsvg
protein
surfac
figur
dual
label
spike
protein
also
show
coloc
figur
indic
pseudoviru
may
contain
vesicl
addit
h
incub
vesicl
observ
figur
treatment
result
similar
observ
follow
treatment
spike
protein
alon
moreov
treatment
ammonium
chlorid
bafilomycin
chloroquin
gfpcontain
vesicl
detect
even
incub
figur
unpublish
data
suggest
reagent
inhibit
receptor
recycl
result
nearli
ident
obtain
follow
spike
protein
treatment
indic
sarscov
may
enter
cell
via
endocytosi
although
pseudoviru
express
gfp
green
vesicl
observ
cell
time
point
result
cellular
rather
viral
express
gfp
express
viral
gfp
gene
observ
h
infect
notion
verifi
cell
gfp
express
observ
h
postinfect
pseudoviru
supplementari
inform
figur
endocyt
pathway
usual
thought
phdepend
therefor
sarscov
enter
cell
via
endocytosi
lysosomotrop
agent
inhibit
viru
infect
vero
cell
report
natur
permiss
sarscov
infect
vero
cell
spikebear
pseudoviru
presenc
absenc
lysosomotrop
agent
sinc
pseudoviru
express
gfp
infect
cell
distinguish
uninfect
cell
viral
gfp
express
figur
show
pseudoviru
infect
vero
cell
lead
viral
gfp
express
lysosomotrop
agent
inhibit
gfp
express
result
suggest
success
viru
entri
phdepend
provid
confirm
sarscov
enter
host
cell
via
endocyt
pathway
dual
immunofluoresc
label
antibodi
specif
sarscov
spike
protein
earli
endosom
marker
protein
earli
endosom
antigen
perform
follow
confoc
microscopi
analysi
h
infect
punctat
pattern
character
strong
coloc
spike
protein
observ
confirm
sarscov
target
earli
endosom
figur
alexalabel
transferrin
use
posit
control
figur
sinc
endocytosi
transferrin
well
character
bind
transferrin
receptor
complex
shown
intern
coat
vesicl
follow
fusion
endosom
thu
spikebear
pseudoviru
like
spike
protein
caus
receptor
transloc
phdepend
manner
pseudoviru
infect
vero
cell
phdepend
manner
addit
pseudoviru
target
earli
endosom
enter
cell
taken
togeth
result
indic
spikebear
pseudoviru
enter
cell
via
endocytosi
determin
sarscov
enter
cell
via
endocytosi
attempt
identifi
specif
endocyt
pathway
exploit
viru
endocyt
pathway
exploit
anim
virus
enter
host
cell
includ
macropinocytosi
clathrindepend
pathway
caveolaedepend
pathway
well
rout
well
character
clathrin
caveolaeindepend
pathway
clathrindepend
pathway
common
pathway
drug
produc
pleiotrop
effect
employ
sever
complementari
approach
determin
role
clathrinmedi
endocytosi
entri
sarscov
cell
chlorpromazin
cpz
drug
commonli
use
inhibit
clathrinmedi
endocytosi
caus
clathrin
lattic
assembl
endosom
membran
prevent
assembl
coat
pit
cell
surfac
effect
cpz
clathrinmedi
endocytosi
first
test
transferrin
label
alexa
alexa
tf
use
vero
cell
mocktreat
cell
transferrin
appear
cluster
perinuclear
region
cpztreat
cell
transferrin
uptak
block
leav
transferrin
cell
surfac
figur
result
confirm
effect
cpz
test
effect
cpz
spikepseudoviru
entri
use
two
differ
method
confoc
microscopi
spectrofluoromet
measur
vero
cell
treat
cpz
incub
spikebear
pseudovirus
h
abil
spikebear
pseudoviru
enter
vero
cell
examin
use
confoc
microscopi
figur
show
spikebear
pseudoviru
enter
vero
cell
despit
cpz
treatment
order
quantifi
effect
cpz
viral
entri
vero
cell
treat
indic
amount
cpz
infect
spikebear
pseudovirus
rel
infect
virus
determin
measur
level
gfp
express
h
postinfect
use
spectrofluoromet
result
demonstr
cpz
significantli
inhibit
viru
entri
figur
use
specif
sirna
approach
explor
role
clathrinmedi
endocytosi
sarscov
entri
cell
use
high
transfect
effici
cell
transfect
sirna
specif
clathrin
heavi
chain
hc
control
sirna
seventytwo
hour
posttransfect
effect
sirna
assay
use
western
blot
cell
infect
pseudovirus
anoth
h
cell
lyse
viral
gfp
express
quantifi
use
spectrofluoromet
although
express
clathrin
hc
knockeddown
cell
transfect
specif
sirna
compar
cell
transfect
control
sirna
infect
viru
significantli
affect
figur
employ
dominantneg
variant
explor
role
clathrinmedi
endocytosi
sarscov
entri
play
import
role
clathrinmedi
endocytosi
express
dominantneg
construct
report
inhibit
clathrinmedi
endocytosi
construct
use
control
confirm
disrupt
clathrindepend
endocyt
pathway
transfect
cell
incub
transferrin
expect
construct
construct
success
inhibit
transferrin
uptak
figur
howev
found
sarscov
abl
enter
cell
express
effici
enter
cell
express
figur
demonstr
express
dominantneg
variant
block
sarscov
entri
result
indic
sarscov
abl
enter
cell
lack
function
clathrindepend
endocyt
pathway
caveolaedepend
endocytosi
newli
character
endocytosi
pathway
caveola
small
flaskshap
invagin
plasma
membran
compos
high
level
cholesterol
glycosphingolipid
well
integr
membran
protein
caveolin
cholesterol
promin
compon
lipid
raft
involv
caveola
format
sequestr
cholesterol
sterolbind
drug
filipin
nystatin
impair
caveolaemedi
endocytosi
determin
whether
sarscov
enter
cell
caveolaemedi
pathway
treat
cell
filipin
nystatin
control
effect
drug
caveolaemedi
endocytosi
examin
measur
uptak
cholera
toxin
subunit
b
ctb
sinc
target
caveola
uptak
block
kind
drug
data
present
figur
indic
drug
block
ctb
uptak
sinc
ctb
cluster
cell
surfac
follow
drug
treatment
compar
concentr
near
nucleu
mocktreat
cell
supplementari
inform
figur
treat
cell
infect
pseudoviru
viru
entri
inhibit
treatment
filipin
nystatin
figur
inhibit
anoth
drug
figur
oligosaccharid
use
deplet
cholesterol
cell
membran
effect
drug
viru
entri
measur
quantit
treatment
vero
cell
shown
inhibit
pseudoviru
entri
dosedepend
manner
figur
filipin
nystatin
inhibitori
effect
viru
entri
figur
studi
whether
caveolaedepend
pathway
involv
endocytosi
viru
coloc
assay
spike
protein
perform
infect
cell
immunolabel
sarscov
spike
protein
marker
pseudovirus
marker
caveola
signific
coloc
pseudoviru
specif
signal
observ
figur
taken
togeth
result
indic
sarscov
abl
enter
cell
caveolinindepend
manner
virus
obligatori
intracellular
parasit
must
enter
host
cell
initi
life
cycl
entri
envelop
virus
cell
known
occur
via
two
primari
pathway
virus
deliv
genom
cytosol
envelop
fuse
plasma
membran
cell
surfac
wherea
other
take
advantag
cell
endocyt
machineri
direct
membran
fusion
cell
surfac
phindepend
entri
via
endocyt
pathway
usual
depend
low
ph
endocyt
vesicl
previous
thought
viru
use
either
direct
membran
fusion
cell
surfac
endocytosi
enter
cell
howev
recent
studi
found
distinct
absolut
exampl
hiv
first
thought
enter
cell
via
direct
membran
fusion
use
endocyt
pathway
also
report
except
newcastl
diseas
viru
also
report
enter
cell
via
direct
fusion
plasma
membran
via
endocyt
pathway
electron
microscopi
viru
entri
experi
demonstr
phindepend
sarscov
infect
led
belief
viru
enter
cell
result
direct
membran
fusion
later
studi
howev
suggest
endocytosi
pathway
may
also
involv
viru
entri
observ
receptor
transloc
recycl
phdepend
viral
entri
earli
endosom
locat
viral
spike
protein
indic
sarscov
pseudovirus
may
enter
cell
via
receptordepend
phsensit
endocytosi
classic
endocytosi
pathway
move
vesicl
earli
endosom
late
endosom
lysosom
intern
cargo
degrad
acid
environ
variou
enzym
thu
possibl
endocyt
viral
entri
may
lead
nonproduct
infect
virus
degrad
lysosom
experi
howev
found
viral
gene
extens
express
cell
line
test
gfp
protein
encod
pseudoviru
vector
first
express
h
postinfect
supplementari
inform
figur
time
point
viral
produc
gfp
evenli
distribut
cytoplasm
vero
cell
cell
cell
mention
prior
infect
major
gfp
local
cell
surfac
cell
supplementari
inform
figur
therefor
endocyt
entri
sarscov
result
product
infect
recent
research
demonstr
numer
virus
employ
endocyt
machineri
cell
infect
cell
endocyt
pathway
use
includ
clathrinmedi
endocytosi
caveola
macropinocytosi
novel
clathrin
caveolaeindepend
pathway
clathrinmedi
endocytosi
common
pathway
numer
virus
use
pathway
enter
cell
includ
semliki
forest
viru
sfv
vesicular
stomat
viru
vsv
hepat
c
viru
hcv
adenovirus
therefor
first
determin
whether
sarscov
enter
cell
clathrinmedi
endocytosi
combin
approach
cpzmediat
inhibit
clathrin
heavi
chain
knockdown
dominantneg
show
sarscov
infect
cell
absenc
clathrinmedi
endocytosi
recent
caveolaemedi
endocytosi
describ
caveola
cholesterol
sphingolipidrich
smooth
invagin
plasma
membran
gener
associ
caveolin
ebola
viru
report
use
pathway
caveolaemedi
endocytosi
disrupt
drug
sequest
cholesterol
plasma
membran
order
defin
role
caveolaemedi
endocytosi
sarscov
entri
use
sever
drug
affect
pathway
nystatin
filipin
experi
neither
nystatin
filipin
inhibit
viru
entri
abl
block
viru
entri
dosedepend
manner
agreement
previou
report
li
et
al
result
togeth
fact
dual
immunostain
show
sarscov
coloc
suggest
deplet
cholesterol
inhibit
sarscov
entri
interf
caveolaemedi
endocytosi
per
se
like
alter
integr
membran
lipid
microdomain
therefor
result
suggest
caveolaemedi
endocytosi
involv
entri
sarscov
find
agreement
fact
sarscov
infect
colon
carcinoma
cell
line
devoid
final
virus
enter
cell
via
macropinocytosi
nonspecif
intern
mechan
requir
receptor
instead
endocyt
vesicl
form
respons
cell
stimul
caus
lamellipodia
site
membran
ruffl
close
form
larg
irregular
vesicl
known
macropinosom
wide
varieti
virus
report
use
macropinocytosi
gain
entri
host
cell
macropinosom
acidifi
intersect
endocyt
vesicl
process
macropinocytosi
requir
actin
therefor
commonli
use
inhibitor
macropinocytosi
cytochalasin
found
treatment
vero
cell
cytochalasin
slightli
inhibit
viral
infect
supplementari
inform
figur
howev
macropinocytosi
unlik
main
pathway
entri
sarscov
sinc
sarscov
pseudovirus
induc
receptor
transloc
cell
surfac
intracellular
compart
macropinocytosi
depend
receptor
recent
anoth
group
report
sarscov
may
enter
hepatocellular
carcinoma
cell
line
clathrinmedi
endocytosi
importantli
clathrinmedi
endocytosi
primarili
receptormedi
previou
research
shown
liver
tissu
larg
neg
low
protein
express
although
author
also
use
engin
cell
express
otherwis
lack
endogen
express
cell
line
atyp
cell
model
sarscov
studi
sinc
vero
cell
rel
high
level
express
wide
use
sarscov
research
precis
pathway
sarscov
enter
vero
cell
need
elucid
studi
use
sever
complementari
approach
investig
sarscov
entri
vero
cell
includ
cpz
inhibit
clathrin
knockdown
dominateneg
provid
direct
evid
addit
direct
membran
fusion
sarscov
enter
cell
endocyt
rout
endocyt
infect
lead
viral
gene
express
endocyt
entri
could
expand
cellular
rang
sarscov
may
explain
replic
sarscov
colon
enterocyt
liver
tissu
macropinocytosisdepend
entri
requir
specif
receptor
result
also
suggest
sarscov
abl
enter
cell
receptormedi
clathrinindepend
caveolaeindepend
endocytosi
like
process
involv
lipid
raft
previou
report
show
cholesterol
extract
treatment
slightli
reduc
express
cell
surfac
vero
cell
importantli
direct
coloc
lipid
raft
scenario
similar
coreceptor
despit
preferenti
associ
nonraft
membran
fraction
cell
requir
cholesterol
normal
function
observ
explain
complic
conform
chang
occur
viru
entri
exampl
case
viru
bind
complex
may
either
leav
raft
compart
order
associ
outsid
raft
stimul
entri
raft
similar
scenario
may
exist
sarscov
although
directli
local
raft
unknown
factor
involv
viru
entri
may
local
lipid
raft
detail
experi
necessari
determin
whether
host
factor
involv
viru
entri
whether
local
lipid
raft
interact
facilit
viru
entri
lipid
raft
sphingolipid
cholesterolrich
domain
plasma
membran
contain
varieti
signal
transport
protein
lipid
raft
signal
report
import
pathogenesi
mani
diseas
microdomain
plasma
membran
pharmacolog
target
prevent
treat
diseas
sarscov
known
caus
acut
respiratori
distress
syndrom
ard
lead
caus
death
due
sarscov
infect
well
hemophagocyt
syndrom
lymphoid
deplet
skelet
muscl
fiber
necrosi
result
elev
level
proinflammatori
cytokin
previou
studi
show
ard
caus
sarscov
mediat
system
decreas
level
protein
due
downregul
transcript
unpublish
data
fact
endocyt
entri
sarscov
involv
lipid
raft
provid
new
insight
ard
pathogenesi
open
new
avenu
could
elucid
molecular
pathogenesi
elev
proinflammatori
cytokin
level
find
highli
relev
develop
futur
therapi
direct
sarscov
date
specif
antivir
drug
shown
effect
treat
sar
character
molecular
pathogenesi
sarscov
evalu
novel
target
led
suggest
entri
inhibitor
may
prove
valuabl
treatment
diseas
find
provid
addit
inform
use
drug
design
peak
plasmid
provid
dr
brian
seed
encod
human
human
control
plasmid
transfect
cell
lipofectamin
invitrogen
puromycinresist
clone
high
level
express
detect
use
western
blot
fluoresc
microscopi
respect
cell
stabli
express
gener
use
method
describ
protein
purifi
protein
column
ge
healthcar
protein
concentr
measur
protein
assay
kit
biorad
spike
proteinbear
pseudotyp
viru
stock
produc
previous
report
briefli
cell
cotransfect
pqcxix
vector
spikeencod
plasmid
provid
dr
michael
farzan
control
plasmid
vsvg
gagpol
express
plasmid
pqcxix
vector
engin
insert
egfp
gene
h
posttransfect
viru
supernat
harvest
filter
pores
filter
viral
stock
aliquot
frozen
viru
titer
determin
previous
describ
cell
cell
seed
onto
plate
twentyfour
hour
later
supernat
contain
spikebear
pseudovirus
control
pseudoviru
fc
equimolar
amount
protein
ad
cell
incub
cell
observ
fluoresc
microscop
experi
use
lysosomotrop
reagent
cell
pretreat
mm
nm
bafilomycin
chloroquin
sigma
h
cell
treat
h
protein
solut
pseudoviru
supernat
contain
reagent
concentr
follow
incub
cell
return
solut
contain
reagent
without
protein
pseudovirus
h
cell
observ
leica
fluoresc
confoc
microscop
vero
cell
grown
coverslip
approxim
confluenc
spininfect
pseudoviru
one
hour
postinfect
cell
fix
pfa
permeabil
triton
block
bsa
cell
probe
primari
antibodi
h
antibodi
santa
cruz
biotechnolog
antispik
antibodi
produc
previous
describ
three
wash
pb
detect
alexa
fluor
goat
antirabbit
antibodi
molecular
probe
detect
alexa
fluor
rabbit
antigoat
antibodi
molecular
probe
spike
protein
detect
alexa
fluor
goat
antimous
antibodi
molecular
probe
cell
wash
three
time
pb
mount
glass
slide
dominantneg
protein
assay
vero
cell
transfect
plasmid
encod
provid
alexandr
benmerah
dr
du
feng
lipofectamin
fortyeight
hour
later
cell
infect
pseudoviru
immunolabel
describ
pseudovirus
immunolabel
antispik
antibodi
detect
alexa
fluor
goat
antimous
secondari
antibodi
primari
secondari
antibodi
use
dilut
respect
imag
obtain
leica
confoc
microscop
receptor
transloc
immunolabel
experi
confoc
microscopi
sequenti
confoc
analys
perform
use
leica
laserscan
spectrum
confoc
system
link
microscop
leica
tc
specif
pmt
adjust
gfp
nm
use
appropri
imag
captur
use
oil
object
planapo
room
temperatur
confoc
acquisit
softwar
lc
leica
imag
bright
contrast
adjust
appli
entir
imag
use
adob
photoshop
drug
inhibit
experi
carri
previous
describ
briefli
vero
cell
pretreat
indic
amount
cpz
nystatin
filipin
cytochalasin
sigma
min
infect
confoc
microscopi
analys
treat
cell
incub
pseudoviru
h
fix
probe
antispik
primari
antibodi
goat
antimous
antibodi
molecular
probe
describ
spectrofluorometri
experi
treat
cell
infect
pseudoviru
h
presenc
drug
fresh
medium
ad
cell
incub
cell
lyse
lysi
buffer
mm
nacl
mm
trishcl
ph
sodium
azid
edta
ph
dtt
presenc
pmsf
proteas
inhibitor
cell
debri
remov
centrifug
rpm
min
gfp
quantifi
spectrofluoromet
perkinelm
excit
wavelength
nm
emiss
nm
data
normal
total
cell
lysat
protein
concentr
measur
biorad
kit
sirna
assay
carri
previous
describ
briefli
cell
cell
transfect
sirna
direct
clathrin
hc
pmol
santa
cruz
biotechnolog
control
sirna
use
lipofectamin
seventytwo
hour
later
effect
sirna
treatment
determin
western
blot
use
clathrin
hc
antibodi
santa
cruz
parallel
cell
infect
sar
pseudoviru
gfp
express
examin
h
later
describ
vero
cell
plate
coverslip
day
use
cell
pretreat
transfect
describ
incub
transferrin
ctb
molecular
probe
ml
min
cell
transfer
h
unintern
ligand
remov
wash
glycin
nacl
ph
cell
fix
analyz
compar
fcinduc
receptor
transloc
cell
contain
obviou
vesicl
count
posit
incub
order
elimin
potenti
bia
research
cell
count
analyz
colleg
student
shenyang
pharmaceut
univers
xiangwu
ju
relat
result
present
mean
sd
least
three
independ
experi
mean
valu
statist
compar
use
twotail
student
ttest
confid
level
supplementari
inform
link
onlin
version
paper
cell
research
websit
